FDA slaps partial hold on MacroGenics for bispecific cancer trials as liver tox spurs safety fears

Leery about signs of liver toxicity among patients taking a B7-H3 × CD3 bispecific under development at MacroGenics $MGNX, the FDA has slapped a partial hold on the early-stage program.